Search
Dexamethasone Treatment Options in Cincinnati, OH
A collection of 102 research studies where Dexamethasone is the interventional treatment. These studies are located in the Cincinnati, OH. Dexamethasone is used for conditions such as Multiple Myeloma, Lymphoma and Postoperative Pain.
37 - 48 of 102
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Type 2 Diabetes Clinical Trial
Recruiting
Can changing your breakfast improve your type 2 diabetes? If you have an HbA1C of 7.0% or higher, you are invited to participate in an online study at the University of Michigan.
Conditions:
Type 2 Diabetes
Diabetes Mellitus Type 2 in Obese
Diabetes Type Two
Type 2 Diabetes Mellitus
Diabete Type 2
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with CareGLP to offer trusted access to GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia
Active Not Recruiting
This phase III trial studies tretinoin and arsenic trioxide in treating patients with newly diagnosed acute promyelocytic leukemia. Standard treatment for acute promyelocytic leukemia involves high doses of a common class of chemotherapy drugs called anthracyclines, which are known to cause long-term side effects, especially to the heart. Tretinoin may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Arsenic trioxide may stop the growth of cancer cells by e... Read More
Gender:
ALL
Ages:
Between 12 months and 21 years
Trial Updated:
10/28/2024
Locations: Children's Hospital Medical Center of Akron, Akron, Ohio +6 locations
Conditions: Acute Promyelocytic Leukemia With t(15;17)(q24.1;q21.2); PML-RARA
Ribociclib in Combination With Everolimus and Dexamethasone in Relapsed ALL
Active Not Recruiting
This research study is evaluating a drug called ribociclib (LEE011) given in combination with everolimus and other standard of care chemotherapy drugs as a possible treatment for relapsed or refractory ALL.
The names of the drugs involved in this study are:
* ribociclib
* everolimus
* dexamethasone
Gender:
ALL
Ages:
Between 1 year and 30 years
Trial Updated:
10/22/2024
Locations: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
Conditions: Acute Lymphoblastic Leukemia ALL
Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies
Completed
Primary Objective:
Phase 1:
To determine the maximum tolerated dose (MTD)/maximum administered dose (MAD) of SAR650984 (Isatuximab).
Phase 2 (stage 1):
To evaluate the activity of single-agent Isatuximab at different doses/schedules and to select dose and regimen to further evaluate the overall response rate (ORR) of Isatuximab as single agent or in combination with dexamethasone.
Phase 2 (stage 2):
To evaluate the activity in terms of overall response rate (ORR) of Isatuximab at the selec... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/22/2024
Locations: University of Cincinnati Site Number : 840004, Cincinnati, Ohio
Conditions: Hematological Malignancy
Study of Axicabtagene Ciloleucel Given With Steroids In Participants With Relapsed Or Refractory Large B-Cell Lymphoma
Active Not Recruiting
The goal of this clinical study is to learn more about the study drug, axicabtagene ciloleucel, in participants with relapsed or refractory large B-cell lymphoma (LBCL) in the outpatient setting.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/03/2024
Locations: Oncology Hematology Care Clinical Trials, LLC, Cincinnati, Ohio
Conditions: Relapsed or Refractory Large B-cell Lymphoma
A Study Comparing Once-weekly vs Twice-weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Completed
Compare efficacy of 56 mg/m2 carfilzomib administered once-weekly in combination with lenalidomide and dexamethasone (KRd 56 mg/m2) to 27 mg/m2 carfilzomib administered twice-weekly in combination with lenalidomide and dexamethasone (KRd 27 mg/m2) in subjects with relapsed or refractory multiple myeloma (RRMM) with 1 to 3 prior lines of therapy.
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
08/09/2024
Locations: Oncology Hematology Care Inc, Cincinnati, Ohio
Conditions: Relapsed or Refractory Multiple Myeloma
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
Recruiting
This phase III trial compares the combination of four drugs (daratumumab, bortezomib, lenalidomide and dexamethasone) to the use of a three drug combination (daratumumab, lenalidomide and dexamethasone). Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as lenalidomide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spread... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/08/2024
Locations: UHHS-Chagrin Highlands Medical Center, Beachwood, Ohio +75 locations
Conditions: Plasma Cell Myeloma, RISS Stage I Plasma Cell Myeloma, RISS Stage II Plasma Cell Myeloma
Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
Recruiting
This phase III trial studies how well lenalidomide and dexamethasone works with or without daratumumab in treating patients with high-risk smoldering myeloma. Drugs used in chemotherapy, such as lenalidomide and dexamethasone, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as daratumumab, may induce changes in the body's immune system and may... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/08/2024
Locations: Indu and Raj Soin Medical Center, Beavercreek, Ohio +72 locations
Conditions: Smoldering Plasma Cell Myeloma
131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma
Active Not Recruiting
A Phase 2 study investigating the addition of cRIT 131I-omburtamab to irinotecan, temozolomide, and bevacizumab for patients with recurrent medulloblastoma. A feasibility cohort is included to assess the feasibility of incorporating cRIT 131I-omburtamab for patients with recurrent ependymoma.
Direct intraventricular delivery of radiolabeled tumor-specific antibodies may aid in both the detection and treatment of recurrent disease for these highly specific pediatric patients with recurrent tumor... Read More
Gender:
ALL
Ages:
21 years and below
Trial Updated:
08/02/2024
Locations: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
Conditions: Recurrent Medulloblastoma, Recurrent Ependymoma
Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma
Completed
This Phase 3, 2-arm, randomized, active comparator-controlled, open-label, multicenter study will compare the efficacy and health-related quality of life (HR-QoL) and assess the safety of selinexor plus bortezomib (Velcade) plus low-dose dexamethasone (SVd) versus bortezomib plus low-dose dexamethasone (Vd) in adult patients with RRMM who have received 1 to 3 prior anti-multiple myeloma (MM) regimens. Crossover from the Vd Arm to a treatment that includes selinexor (i.e., SVdX or SdX) will be al... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/25/2024
Locations: University of Cincinnati Health, Cincinnati, Ohio
Conditions: Multiple Myeloma
Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia
Completed
The purpose of Phase 1b of this study is to:
* Asses the safety, tolerability and activity of carfilzomib, alone and in combination with induction chemotherapy, in children with relapsed or refractory acute lymphoblastic leukemia (ALL).
* Determine the maximum tolerated dose (MTD) and to recommend a phase 2 dose of carfilzomib in combination with induction chemotherapy.
The purpose of Phase 2 of this study is to compare the rate of complete remission (CR) of carfilzomib in combination with vin... Read More
Gender:
ALL
Ages:
Between 1 month and 21 years
Trial Updated:
07/13/2024
Locations: Cincinnati Childrens Hospital Medical Center, Cincinnati, Ohio +2 locations
Conditions: Acute Lymphoblastic Leukemia (ALL)
Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
Completed
This phase III trial studies combination chemotherapy with or without lestaurtinib with to see how well they work in treating younger patients with newly diagnosed acute lymphoblastic leukemia. Drugs used in chemotherapy work in different ways to stop the growth of stop cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Lestaurtinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. It is not yet... Read More
Gender:
ALL
Ages:
1 year and below
Trial Updated:
07/03/2024
Locations: Children's Hospital Medical Center of Akron, Akron, Ohio +7 locations
Conditions: Acute Lymphoblastic Leukemia, Acute Undifferentiated Leukemia, Childhood T Acute Lymphoblastic Leukemia
A Study to Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
Withdrawn
The purpose of this study is to evaluate the efficacy and safety of alnuctamab compared to standard of care regimens in participants with relapsed or refractory multiple myeloma (RRMM).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/30/2024
Locations: Local Institution - 0306, Cincinnati, Ohio +1 locations
Conditions: Multiple Myeloma
37 - 48 of 102